DANIELA REGAZZO

Dr. DANIELA REGAZZO

University of Padua, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2013 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GOGianluca Occhi
Gianluca Occhi
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
GTGiampaolo Trivellin
Giampaolo Trivellin
FBFrancesca Boaretto
Francesca Boaretto
DCDenis Ciato
Denis Ciato
CSCarla Scaroni
Carla Scaroni
The CDKN1B gene encodes the cyclin-dependent kinase inhibitor p27KIP1, an atypical tumor suppressor playing a key role in cell cycle regulation, cell proliferation, and differentiation. Impaired p27KIP1 expression and/or localization are often observed in tumor cells, further confirming its central role in regulating the cell cycle. Recently, germline mutations in CDKN1B have been associated with the inherited multiple endocrine neoplasia syndrome type 4, an autosomal dominant syndrome characterized by varying combinations of tumors affecting at least two endocrine organs. In this study we identified a 4-bp deletion in a highly conserved regulatory upstream ORF (uORF) in the 5′UTR of the CDKN1B gene in a patient with a pituitary adenoma and a well-differentiated pancreatic neoplasm. This deletion causes the shift of the uORF termination codon with the consequent lengthening of the uORF–encoded peptide and the drastic shortening of the intercistronic space. Our data on the immunohistochemical analysis of the patient's pancreatic lesion, functional studies based on dual-luciferase assays, site-directed mutagenesis, and on polysome profiling show a negative influence of this deletion on the translation reinitiation at the CDKN1B starting site, with a consequent reduction in p27KIP1 expression. Our findings demonstrate that, in addition to the previously described mechanisms leading to reduced p27KIP1 activity, such as degradation via the ubiquitin/proteasome pathway or non-covalent sequestration, p27KIP1 activity can also be modulated by an uORF and mutations affecting uORF could change p27KIP1 expression. This study adds the CDKN1B gene to the short list of genes for which mutations that either create, delete, or severely modify their regulatory uORFs have been associated with human diseases. Gene expression can be modulated at different steps on the way from DNA to protein including control of transcription, translation, and post-translational modifications. An abnormality in the regulation of mRNA and protein expression is a hallmark of many human diseases, including cancer. In some eukaryotic genes translation can be influenced by small DNA sequences termed upstream open reading frames (uORFs). These elements located upstream to the gene start codon may either negatively influence the ability of the translational machinery to reinitiate translation of the main protein or, much less frequently, stimulate protein translation by enabling the ribosomes to bypass cis-acting inhibitory elements. CDKN1B, which encodes the cell cycle inhibitor p27KIP1, includes an uORF in its 5′UTR sequence. p27KIP1 expression is often reduced in cancer, and germline mutations have been identified in CDKN1B in patients affected with a syndrome (MEN4) characterized by varying combinations of tumors in endocrine glands. Here we show that a small deletion in the uORF upstream to CDKN1B reduces translation reinitiation efficiency, leading to underexpression of p27KIP1 and coinciding with tumorigenesis. This study describes a novel mechanism by which p27KIP1 could be underexpressed in human tumors. In addition, our data provide a new insight to the unique pathogenic potential of uORFs in human diseases.

15 April 2010 in Molecular Nutrition & Food Research
Verified
Journal Article
Closed access
PDF file
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
DMDaniel Mollé
Daniel Mollé
Gianfranco GabaiGianfranco Gabai
Gianfranco Gabai
DTDaniel Tomé
Daniel Tomé
DDDidier DUPONT
Didier DUPONT
RBRachel Boutrou
Rachel Boutrou

19 April 2016 in Endocrine
Verified
Journal Article
Closed access
PDF file
NAN. M. Albiger
N. M. Albiger
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
BRB. Rubin
B. Rubin
AFA. M. Ferrara
A. M. Ferrara
SRS. Rizzati
S. Rizzati
CSCarla Scaroni
Carla Scaroni

1 May 2017 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
MLM Losa
M Losa
NAN M Albiger
N M Albiger
MTM R Terreni
M R Terreni
GVG Vazza
G Vazza
GOGianluca Occhi
Gianluca Occhi
Objective: Glucose-dependent insulinotropic polypeptide receptor (GIPR) overexpression has been recently described in a proportion ofgsp−somatotropinomas and suggested to be associated with the paradoxical increase of GH (GH-PI) during an oral glucose load.Design and methods: This study was aimed at linking the GIP/GIPR pathway to GH secretion in 25 somatotropinomas-derived primary cultures and correlating molecular with clinical features in acromegalic patients. Given the impairment of the GIP/GIPR axis in acromegaly, an additional aim was to assess the effect of GH/IGF-1 stimulation on GIP expression in the enteroendocrine cell line STC-1.Results: Nearly 80% ofGIPR-expressing somatotropinomas, all of them negative forgspmutations, show increased GH secretion upon GIP stimulation, higher sensitivity to Forskolin but not to somatostatin analogs. Besides increased frequency of GH-PI,GIPRoverexpression does not appear to affect acromegalic patients’ clinical features. In STC-1 cells transfected with GIP promoter-driven luciferase vector, IGF-1 but not GH induced dose-dependent increase in luciferase activity.Conclusions: We demonstrate thatGIPRmediates the GH-PI in a significant proportion ofgsp−acromegalic patients. In these cases, the stimulatory effect of IGF-1 on GIP promoter support the hypothesis of a functional GH/IGF-1/GIP axis. Further studies based on larger cohorts and the development of a stable transgenic model with inducible GIPR overexpression targeted to pituitary somatotroph lineage will be mandatory to establish the real role of GIPR in the pathogenesis of somatotropinomas.

7 May 2011 in Journal of Neuroendocrinology
Verified
Journal Article
Closed access
PDF file
GOGianluca Occhi
Gianluca Occhi
MLM. Losa
M. Losa
NAN. Albiger
N. Albiger
GTGiampaolo Trivellin
Giampaolo Trivellin
DANIELA REGAZZODANIELA REGAZZO
DANIELA REGAZZO
CSCarla Scaroni
Carla Scaroni

Verified
Journal Article
Open access
PDF file
Filippo CrimiFilippo Crimi
Filippo Crimi
Emilio QuaiaEmilio Quaia
Emilio Quaia
GCGiulio Cabrelle
Giulio Cabrelle
Chiara ZanonChiara Zanon
Chiara Zanon
Alessia PepeAlessia Pepe
Alessia Pepe
FCFilippo Ceccato
Filippo Ceccato
Adrenal incidentalomas (AIs) are incidentally discovered adrenal neoplasms. Overt endocrine secretion (glucocorticoids, mineralocorticoids, and catecholamines) and malignancy (primary or metastatic disease) are assessed at baseline evaluation. Size, lipid content, and washout characterise benign AIs (respectively, <4 cm, <10 Hounsfield unit, and rapid release); nonetheless, 30% of adrenal lesions are not correctly indicated. Recently, image-based texture analysis from computed tomography (CT) may be useful to assess the behaviour of indeterminate adrenal lesions. We performed a systematic review to provide the state-of-the-art of texture analysis in patients with AI. We considered 9 papers (from 70 selected), with a median of 125 patients (range 20–356). Histological confirmation was the most used criteria to differentiate benign from the malignant adrenal mass. Unenhanced or contrast-enhanced data were available in all papers; TexRAD and PyRadiomics were the most used software. Four papers analysed the whole volume, and five considered a region of interest. Different texture features were reported, considering first- and second-order statistics. The pooled median area under the ROC curve in all studies was 0.85, depicting a high diagnostic accuracy, up to 93% in differentiating adrenal adenoma from adrenocortical carcinomas. Despite heterogeneous methodology, texture analysis is a promising diagnostic tool in the first assessment of patients with adrenal lesions.